Biohaven ROA 2016-2023 | BHVN
Current and historical return on assets (ROA) values for Biohaven (BHVN) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Biohaven ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2023-03-31 |
$-0.54B |
$0.62B |
-77.49% |
| 2022-12-31 |
$-0.57B |
$0.66B |
-64.12% |
| 2022-09-30 |
$-0.29B |
$0.14B |
-38.34% |
| 2022-06-30 |
$-0.28B |
$1.39B |
-27.39% |
| 2022-03-31 |
$-0.05B |
$1.37B |
-5.27% |
| 2021-12-31 |
$-0.21B |
$0.14B |
-27.42% |
| 2021-09-30 |
$-0.10B |
$1.13B |
-10.91% |
| 2021-06-30 |
$-0.24B |
$0.85B |
-29.05% |
| 2021-03-31 |
$-0.21B |
$1.00B |
-29.14% |
| 2020-12-31 |
$-0.12B |
$0.69B |
-19.62% |
| 2020-09-30 |
$-0.70B |
$0.78B |
-160.55% |
| 2020-06-30 |
$-0.61B |
$0.42B |
-174.50% |
| 2020-03-31 |
$-0.64B |
$0.53B |
-174.71% |
| 2019-12-31 |
$-0.53B |
$0.00B |
-179.74% |
| 2019-09-30 |
$-0.43B |
$0.44B |
-118.50% |
| 2019-06-30 |
$-0.39B |
$0.49B |
-127.44% |
| 2019-03-31 |
$-0.22B |
$0.25B |
-89.58% |
| 2018-12-31 |
$-0.24B |
$0.29B |
-112.94% |
| 2018-09-30 |
$-0.21B |
$0.20B |
-119.94% |
| 2018-06-30 |
$-0.19B |
$0.24B |
-111.33% |
| 2018-03-31 |
$-0.20B |
$0.13B |
-119.64% |
| 2017-12-31 |
$-0.14B |
$0.15B |
-91.75% |
| 2017-09-30 |
$-0.14B |
$0.19B |
-113.58% |
| 2017-06-30 |
$-0.12B |
$0.21B |
-163.46% |
| 2017-03-31 |
$-0.08B |
$0.06B |
-386.21% |
| 2016-12-31 |
$-0.06B |
$0.03B |
-948.15% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.059B |
$0.463B |
|
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
|
